Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol
Teruo Jojima, Shintaro Sakurai, Sho Wakamatsu, Toshie Iijima, Masahiro Saito, Takuya Tomaru, Takahiko Kogai, Isao Usui, Yoshimasa Aso
Topics & Concepts
MedicineEmpagliflozinCampesterolInternal medicineCholesterolEndocrinologyType 2 diabetesDiabetes mellitusLdl cholesterolSterolCholesterol and Lipid MetabolismDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins